| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
3,704 |
4,538 |
27,327 |
202,315 |
| Total Sell Value |
$438,449 |
$537,921 |
$3,641,323 |
$29,586,917 |
| Total People Sold |
1 |
3 |
13 |
19 |
| Total Sell Transactions |
2 |
4 |
21 |
79 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Iannone Robert |
EVP, Global Head of R&D |
• – – |
2022-12-09 |
4 |
S |
$151.54 |
$279,440 |
D/D |
(1,844) |
36,316 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2022-12-05 |
4 |
S |
$152.06 |
$9,580 |
D/D |
(63) |
5,934 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2022-12-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,465) |
46,984 |
|
- |
|
| Smith Mark Douglas |
Director |
– • – |
2022-12-02 |
4 |
S |
$154.68 |
$64,966 |
D/D |
(420) |
5,471 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2022-12-02 |
4 |
S |
$154.68 |
$64,966 |
D/D |
(420) |
5,471 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-12-01 |
4 |
AS |
$157.00 |
$157,000 |
D/D |
(1,000) |
371,078 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2022-11-16 |
4 |
S |
$142.34 |
$499,613 |
D/D |
(3,510) |
26,769 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2022-11-14 |
4 |
S |
$149.33 |
$29,418 |
D/D |
(197) |
19,409 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-11-10 |
4 |
AS |
$150.00 |
$300,000 |
D/D |
(2,000) |
372,028 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-11-10 |
4 |
AS |
$155.00 |
$164,765 |
D/D |
(1,063) |
11,309 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-11-10 |
4 |
OE |
$109.45 |
$116,345 |
D/D |
1,063 |
11,840 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-10-03 |
4 |
AS |
$134.02 |
$6,096,906 |
D/D |
(45,185) |
374,028 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-10-03 |
4 |
OE |
$59.13 |
$3,719,573 |
D/D |
62,905 |
419,213 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2022-09-07 |
4 |
S |
$150.00 |
$9,450 |
D/D |
(63) |
19,606 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-09-06 |
4 |
AS |
$152.41 |
$1,179,970 |
D/D |
(7,703) |
356,308 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2022-09-06 |
4 |
OE |
$59.13 |
$573,561 |
D/D |
9,700 |
363,011 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-09-02 |
4 |
AS |
$156.98 |
$83,356 |
D/D |
(531) |
11,309 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-09-02 |
4 |
OE |
$109.45 |
$58,118 |
D/D |
531 |
11,840 |
|
- |
|
| Gray Peter |
Director |
– • – |
2022-08-18 |
4 |
S |
$158.00 |
$1,264,000 |
D/D |
(8,000) |
14,234 |
|
- |
|
| Gray Peter |
Director |
– • – |
2022-08-18 |
4 |
OE |
$55.28 |
$442,240 |
D/D |
8,000 |
22,234 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2022-08-15 |
4 |
AS |
$156.86 |
$342,854 |
D/D |
(2,142) |
5,934 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2022-08-15 |
4 |
OE |
$113.10 |
$226,200 |
D/D |
2,000 |
7,934 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2022-08-08 |
4 |
S |
$152.33 |
$24,067 |
D/D |
(158) |
6,076 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2022-08-08 |
4 |
S |
$152.32 |
$165,879 |
D/D |
(1,089) |
5,891 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2022-08-08 |
4 |
S |
$152.32 |
$165,877 |
D/D |
(1,089) |
11,871 |
|
- |
|
881 Records found
|
|
Page 5 of 36 |
|
|
0.37 (0.34%) 
